Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

VP-20621 generally well tolerated in phase I study

Sep. 30, 2010

Scientists describe CFTR inhibitors for acute secretory diarrhea

Sep. 30, 2010

Clinical data presented on DiaPep-277 in type 1 diabetes

Sep. 30, 2010

Studies point to potential benefit of ITI-007 in Parkinson's disease

Sep. 29, 2010

SUN-13834 is efficacious in patients with atopic dermatitis

Sep. 29, 2010

CYT-003-QbG-10 is safe and efficacious in allergic asthma

Sep. 29, 2010

Phase I data presented on flu vaccine NB-1008 and acne therapy NB-003

Sep. 29, 2010

Imeglimin shows promise in phase II trials in type 2 diabetes

Sep. 29, 2010

Phase II data on MK-0941 cast doubt on suitability for treatment of diabetes

Sep. 29, 2010

Namisol tablet for multiple sclerosis shows promise in first-in-human trial

Sep. 28, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...